These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 3874911

  • 21. Specific inhibition of hybrid resistance in F1 hybrid mice pretreated with parent strain spleen cells. I. Induction of a nylon-adherent, Thy-1+Lyt-1+2- suppressor cell.
    Kosmatopoulos K, Orbach-Arbouys S.
    J Immunol; 1987 Feb 01; 138(3):704-12. PubMed ID: 2879865
    [Abstract] [Full Text] [Related]

  • 22. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant.
    Nagase F, Ueda K, Kawashima K, Jamshedur Rahman SM, Isobe K, Yoshida T, Hasegawa Y, Ando K, Iwamoto T, Nagura E.
    J Immunol; 1987 Apr 01; 138(7):2359-65. PubMed ID: 2951438
    [Abstract] [Full Text] [Related]

  • 23. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC, Prager MD.
    Cancer Res; 1977 Feb 01; 37(2):507-13. PubMed ID: 832275
    [Abstract] [Full Text] [Related]

  • 24. Requirements for T cell recognition and elimination of retrovirally-transformed cells.
    Greenberg P, Klarnet J, Kern D, Okuno K, Riddell S, Cheever M.
    Princess Takamatsu Symp; 1988 Feb 01; 19():287-301. PubMed ID: 2479634
    [Abstract] [Full Text] [Related]

  • 25. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
    Shima J, Yoshioka T, Kosugi A, Ogata M, Fujiwara H, Hamaoka T, Ueda S, Kato S.
    Biken J; 1987 Mar 01; 30(1):1-8. PubMed ID: 2445335
    [Abstract] [Full Text] [Related]

  • 26. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.
    J Immunol; 1984 Mar 01; 132(3):1571-7. PubMed ID: 6198397
    [Abstract] [Full Text] [Related]

  • 27. [Effects of adult thymectomy on the growth of 203-glioma in mice--analysis of T cell subpopulation in tumor immunology].
    Yamasaki T, Yamashita J, Handa H, Namba Y, Hanaoka M.
    No To Shinkei; 1982 Nov 01; 34(11):1067-75. PubMed ID: 6984337
    [Abstract] [Full Text] [Related]

  • 28. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
    Yoshioka T, Fukuzawa M, Takai Y, Wakamiya N, Ueda S, Kato S, Fujiwara H, Hamaoka T.
    Cancer Immunol Immunother; 1986 Nov 01; 21(3):193-8. PubMed ID: 2938736
    [Abstract] [Full Text] [Related]

  • 29. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
    Ting CC, Rodrigues D.
    J Natl Cancer Inst; 1982 Oct 01; 69(4):867-72. PubMed ID: 6214653
    [Abstract] [Full Text] [Related]

  • 30. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H, Aoki H, Yoshioka T, Tomita S, Ikegami R, Hamaoka T.
    J Immunol; 1984 Jul 01; 133(1):509-14. PubMed ID: 6233375
    [Abstract] [Full Text] [Related]

  • 31. Subsets of oncofetal antigen-induced T-cells: ability to mediate antitumor immune response.
    Gautam S, Deodhar SD.
    J Natl Cancer Inst; 1983 May 01; 70(5):923-30. PubMed ID: 6601736
    [Abstract] [Full Text] [Related]

  • 32. Restoration of impaired T cell functions in tumor-bearing mice by the administration of interleukin 1.
    Yamashita U, Shirakawa F.
    Jpn J Cancer Res; 1987 Mar 01; 78(3):270-8. PubMed ID: 3106283
    [Abstract] [Full Text] [Related]

  • 33. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
    Takatsu K, Hamaoka T, Tominaga A, Kanamasa Y.
    J Immunol; 1980 Dec 01; 125(6):2367-73. PubMed ID: 6776192
    [Abstract] [Full Text] [Related]

  • 34. Prevention of tumor metastasis after surgical removal of primary tumor by using in vitro activated macrophages.
    Okuno K, Hashimoto T, Qian JH, Tsuchida T, Fujiwara H, Hamaoka T.
    Jpn J Clin Oncol; 1985 Mar 01; 15(1):87-94. PubMed ID: 3981817
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Importance of Lyt 1+ T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type Tubercle bacilli.
    Suzuki F, Brutkiewicz RR, Pollard RB.
    J Natl Cancer Inst; 1986 Aug 01; 77(2):441-7. PubMed ID: 3090339
    [Abstract] [Full Text] [Related]

  • 37. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW, Mokyr MB.
    Cancer Res; 1984 Sep 01; 44(9):3873-9. PubMed ID: 6611201
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.